490results about "Carbohydrate active ingredients" patented technology

Provided are compounds of Formula I:nucleosides, nucleoside phosphates and prodrugs thereof, wherein R6 is CN, ethenyl, 2-haloethen-1-yl, or (C2-C8)-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.

The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described.The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.

The disclosure provides an extracorporeal devices, systems and methods for removing a pathogen or a toxin from a biological fluid of a subject comprising contacting a biological fluid from the subject with a loosely packed bed of adsorption media, such as a fluidized bed, wherein the adsorption media comprises heparin, to remove the pathogen or the toxin to form a treated biological fluid; and infusing the treated fluid into the subject.

The present invention relates to compositions comprising polyplex formulations for delivering RNA to target organs or cells after parenteral administration, particularly after intramuscular administration. More specifically, the present invention relates to formulations for the administration of RNA, such as self-replicating RNA, particularly by intramuscular injection. More particularly, the formulations comprise polyplex particles derived from single-stranded RNA and polyalkyleneimine.

Described herein are methods of for treating and / or preventing Major adverse cardiovascular events (MACE). by administering to a subject in need thereof, a combination of a sodium-glucose transport protein 2 (SGLT2) inhibitor and a compound of Formula I or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein the variables of Formula I are as defined herein.

The present application relates to a synbiotic composition for use in the amelioration, treatment, reductions of symptoms of a neuropsychiatric disorder and / or the reduction of side effects of a pharmacological treatment of a neuropsychiatric disorder, wherein the synbiotic composition comprises at least two bacterial strains chosen from the group consisting of Lactobacillus plantarum, Lactobacillus paracasei, Pediococcus pentosaceus, Leuconostoc mesenteroides, and Bifidobacterium breve; and at least one dietary fibers chosen from the group consisting of inulin, pectin, beta-glucan, resistant starch, a galacto-oligosaccharide, an isomalto-oligosaccharide and a rice fiber.

The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatment of certain endothelin related diseases.

Disclosed is a process for the synthesis of mono- and bis-nitrosylated propanediols, as well as compositions and pharmaceutical formulations that includes the compounds. The process proceeds by reacting a corresponding propanediol that is not nitrosylated with a source of nitrite, optionally in the presence of a suitable acid. When the source of nitrite is an organic nitrite, reacting step is performed in a suitable organic solvent, and when the source of nitrite is an inorganic nitrite, the reacting step is performed in a bi-phasic solvent mixture comprising an aqueous phase and a non-aqueous phase. Also disclosed are methods of treating a condition wherein administration of nitric oxide (NO) has a beneficial effect by administering said compounds, compositions or formulations.

Provided are methods for treating cancer using local administration of certain CpG oligonucleotides (CpG ODN) and systemic administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and / or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-α) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.

A method and composition for enhancing adenosine monophosphate-activated protein kinase (AMPK) activity and improving mitochondrial-related oxidative metabolism parameters in motor and sedentary mammals by oral intake of low doses of D-ribose, thereby promoting overall metabolic health in mammals.

The present invention relates to sulforaphane glycoconjugate compounds, as well as to the synthesis and therapeutic uses thereof for treating inflammatory diseases.

Provided herein are methods of ameliorating a disease or condition associated with a disorder of a complement bypass pathway by administering to a subject a complement factor B (CFB) specific inhibitor.

Provided are a composite tablet comprising a first layer containing dry granules containing sitagliptin, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, and dapagliflozin, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, and a second layer containing wet granules containing metformin, or a pharmaceutically acceptable salt thereof, and colloidal silicon dioxide, and a method for producing the same.

Methods and compositions for improving cardiac function and health are disclosed. The methods and compositions are based on urolithin.

The present invention relates to modulators of TNF signalling for use in treating and / or preventing acute pain. In particular, a modulator of TNF signalling may be a tumour necrosis factor receptor 2 (TNFR2) agonist comprising (i) a TNFR2 binding domain comprising three TNF homology domains (THD) that specifically bind to TNFR2; and (ii) an Fc domain. The present invention further relates to combinations of a TNFR2 agonist and an inhibitor of tumour necrosis factor receptor 1 (TNFR1) signalling.

To solve the problem in which: in view of the role played by CD73 in cancer, as well as a diverse array of other diseases, disorders and conditions, and the current lack of CD73 inhibitors available to medical practitioners, new CD73 inhibitors, and compositions and methods associated therewith, are needed.SOLUTION: Compounds that modulate the conversion of AMP to adenosine by 5'-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and / or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5'-nucleotidase, ecto is also provided.SELECTED DRAWING: Figure 1

The present disclosure is directed to methods of reducing the risk of developing Type 2 diabetes and / or treating prediabetes in a patient in need thereof, the method comprising administering to the patient, an effective amount of a sodium-glucose co-transporter 2 (SGLT2) inhibitor, wherein the patient has an HbA1c between 5.7% to 6.4% and / or a fasting glucose between 100 to 125 mg / dl.

The present invention concerns the compound aprocitentan, {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide and its use as endothelin receptor antagonist, in combination with an SGLT-2 inhibitor. The invention further relates to pharmaceutical compositions comprising aprocitentan in combination with said SGLT-2 inhibitor. The invention further relates to such pharmaceutical compositions comprising crystalline forms of aprocitentan.

The present invention relates to the use of one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof in combination with pimobendan and / or telmisartan or pharmaceutically acceptable forms thereof for the prevention and / or treatment of one or more heart diseases in non-human mammals / non-human mammalian animals, such as dogs or cats.

Provided herein are methods of treating IgA nephropathy, comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, to a subject in need thereof Also provided herein are methods of decreasing renal inflammation and / or fibrosis, decreasing the occurrence of hematuria, stabilizing eGFR. decreasing the number of IgA-nephropathy associated disease flares, delaying the onset of ESRD, decreasing proteinuria, and decreasing fatigue in a subject having IgA nephropathy, comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, to the subject. In some embodiments, the subject has not been previously diagnosed with one or more of diabetic nephropathy, HIV / AIDS, HIV-related nephropathy, prostate cancer, or acute kidney failure

The present application relates to a synbiotic composition for use in the amelioration, treatment, reductions of symptoms of a neuropsychiatric disorder and / or the reduction of side effects of a pharmacological treatment of a neuropsychiatric disorder, wherein the synbiotic composition comprises at least two bacterial strains chosen from the group consisting of Lactobacillus plantarum, Lactobacillus paracasei, Pediococcus pentosaceus, Leuconostoc mesenteroides, and Bifidobacterium breve; and at least one dietary fibers chosen from the group consisting of inulin, pectin, beta-glucan, resistant starch, a galacto-oligosaccharide, an isomalto-oligosaccharide and a rice fiber.

To solve the problem in which: in view of the role played by CD73 in cancer, as well as a diverse array of other diseases, disorders and conditions, and the current lack of CD73 inhibitors available to medical practitioners, new CD73 inhibitors, and compositions and methods associated therewith, are needed.SOLUTION: Compounds that modulate the conversion of AMP to adenosine by 5'-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and / or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5'-nucleotidase, ecto is also provided.SELECTED DRAWING: Figure 1

The present disclosure relates to collagen binding modification engineering of anti-inflammatory agents using collagen binding peptides (CBP) and vWF A3 to achieve targeted therapy of inflammatory diseases. Accordingly, embodiments of the present disclosure relate to compositions comprising an anti-inflammatory agent operably linked to an extracellular matrix (ECM) affinity peptide. Also disclosed are cytokines and anti-inflammatory agents, such as CD200, linked to serum proteins and / or ECM affinity peptides. Other aspects of the present disclosure relate to methods for treating an autoimmune or inflammatory disorder in a subject comprising administering to the subject a composition of the present disclosure.

The disclosure generally relates to ready to drink electrolyte solution. In particular the disclosure relates to a ready to drink electrolyte solution comprising isomaltulose, glucose, sodium ions, chromium ions and water; wherein the glucose concentration is greater than or equal to 0.9g / 100ml, and wherein the theoretical glycemic index of the solution is equal to or less than 55. The disclosure also relates to a method of manufacturing said ready to drink electrolyte solution. The disclosure also relates to a method of rehydrating a patient suffering from cancer, diabetes, acute or chronic illness, or a gastrointestinal disorder by using said ready to drink electrolyte solution.

Provided herein are compositions comprising a silicate, inositol, and optionally an amino acid, which have improved solubility and / or are crystalline. Also provided are methods of making the disclosed compositions, as well as methods of making beverages comprising the disclosed compositions.

Provided herein are methods of improving kidney function in a subject in need thereof.

Systems and methods for treating and / or preventing metabolic disorders and / or other medical conditions in patients (e.g., felines) are described, by administering a liquid pharmaceutical composition, preferably containing one or more SGLT-2 inhibitor compounds, to the patient via a delivery system including a syringe. The syringe is characterized by facilitating the simple, safe, and effective dosage of small volume measurements of the liquid pharmaceutical composition to the patient during administration.

Non-caloric carbohydrates, i.e., carbohydrates that do not contribute calories to the diet, have emerged as a new avenue in the modulation of brain metabolism and the extracellular matrix in the context of cognitive aging. In this disclosure, non-caloric monosaccharides such as fucose and galactose were tested for their impact on protein glycosylation and brain metabolism as well as social behavior. The invention generally provides monosaccharide supplements and kits thereof as well as use methods to improve brain function in learning, memory, social interactions, group dynamics, and mood.